MGNX MacroGenics Forecast, Technical & Fundamental Analysis
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer... Show more
MGNX is expected to report earnings to fall 86.57% to -7 cents per share on August 11
Q2'26
Est.
$-0.08
Q1'26
Missed
by $0.01
Q4'25
Missed
by $0.03
Q3'25
Beat
by $0.68
Q2'25
Missed
by $0.11
The last earnings report on May 13 showed earnings per share of -57 cents, missing the estimate of -56 cents. With 60.77K shares outstanding, the current market capitalization sits at 248.53M.
A.I. Advisor
published General Information
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
The Aroon Indicator for MGNX entered a downward trend on May 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 242 similar instances where the Aroon Indicator formed such a pattern. In of the 242 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MGNX moved out of overbought territory on May 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MGNX turned negative on June 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
MGNX moved above its 50-day moving average on May 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.723) is normal, around the industry mean (19.567). P/E Ratio (0.000) is within average values for comparable stocks, (35.932). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.687). MGNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (1.575) is also within normal values, averaging (355.865).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
